2015 REVIEW: China - Quality The Watchword In String Of CFDA Reforms
This article was originally published in PharmAsia News
2015 has seen a plethora of regulatory changes and policy rewinding for China, by many measures now the world's largest pharmaceutical market. If you missed some of the major news during the year, here is your opportunity to check out the top China pharma regulatory happenings in 2015 with the help of one easy to digest infographic.
You may also be interested in...
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.